DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that Presbia will be participating at the 20TH European Society of Cataract & Refractive Surgeons (ESCRS) Winter Meeting. The ESCRS is Europe's leading organization for cataract and refractive surgeons and is at the forefront of development in anterior segment surgery. The event will be held the 26th through 28th of February at Megaron Congress Centre in Athens, Greece.
Vladimir Feingold, Presbia’s Chief Technology Officer and a Presbia board member, will present a Poster at the Meeting featuring an analysis of 275 patients having undergone the implantation of the Presbia Flexivue Microlens™ and an evaluation of their significant improvement in near-vision. The multicenter study was conducted in Japan, Greece, Ireland, Czech Republic and Italy.
“While we have approvals to commercialize the Presbia Flexivue Microlens™ in dozens of countries worldwide, we’re taking a highly-focused approach to create awareness of our surgical solution for near-vision loss. We continue to lay the groundwork for commercialization in Europe, predominately Germany, our next targeted area, and are underway in Asia-Pacific with an increasing presence in South Korea,” said Todd Cooper, President and CEO of Presbia. “The gathering of key industry leaders at the ESCRS winter meeting will further the awareness of our Microlens implant as a groundbreaking treatment for near-vision restoration for patients, eliminating the need for reading glasses.”
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.